Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alcon

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

- PMLiVE

Boehringer Ingelheim promotes Debraj Dasgupta

He will lead on its global marketing and sales platforms

- PMLiVE

Novartis expands eyecare partnership with NHS

And wins new licence for Lucentis

- PMLiVE

US clamps down on tax inversion deals

Will make it harder for companies to dodge taxes overseas

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

- PMLiVE

Alcon names president EMEA

Riad Sherif joins from Novartis’ Canada business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links